Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/15/2024 | $25.00 | Underperform | Wolfe Research | |
| 10/31/2024 | $300.00 | Neutral → Buy | BofA Securities | |
| 10/25/2024 | $30.00 | Neutral | Citigroup | |
| 10/17/2024 | $32.00 | Mkt Perform | Bernstein | |
| 10/10/2024 | $300.00 | Peer Perform → Outperform | Wolfe Research | |
| 8/14/2024 | $250.00 → $240.00 | Outperform → Sector Perform | RBC Capital Mkts | |
| 8/9/2024 | $275.00 → $257.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/7/2024 | Neutral → Outperform | Daiwa Securities |
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Issuer)
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
L3Harris Technologies (NYSE:LHX) today announced that David S. Regnery, Chair and Chief Executive Officer of Trane Technologies plc, has been appointed to its Board of Directors. "Dave is a strong business leader with proven success in business transformation, putting the customer first and creating a culture where innovation and accountability are important drivers of business decisions," said Christopher E. Kubasik, Chair and CEO, L3Harris. "His established track record of leading large organizations and shaping Trane Technologies' future strategy will be important to L3Harris as we continue our journey as the industry's Trusted Disruptor in support of our customers' most critical needs.
Pfizer Inc. (NYSE:PFE) today announced the election of Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard's Chief Investment Officer, overseeing the company's internally managed stock, bond and money market portf
Zai Lab (("Zai Lab", NASDAQ:ZLAB, HKEX: 9688)) and Pfizer (("Pfizer", NYSE:PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through Novem
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
In the EU, HYMPAVZI is the first once-weekly subcutaneous treatment approved for eligible people living with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for people living with severe hemophilia A or B HYMPAVZI's approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with se
Wolfe Research initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00
BofA Securities upgraded L3Harris from Neutral to Buy and set a new price target of $300.00
Citigroup resumed coverage of Pfizer with a rating of Neutral and set a new price target of $30.00
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients.Pfizer Inc. (NYSE:PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to v
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 21 unusual trades. Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $296,355, and 18 were calls, valued at $1,032,173. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $35.0 for Pfizer over the last 3 months. Analyzing Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
Analysts expect L3Harris Technologies, Inc. (NYSE:LHX) to report second-quarter earnings of $3.18 per share after the closing bell on Thursday, July 25. That’s up from $2.97 per share in the year-ago period. Benzinga Pro data projects L3Harris Technologies to post revenue of $5.3 billion, compared to $4.37 billion a year earlier. On July 18, the Melbourne, Florida-based company’s board declared a quarterly cash dividend of $1.16 per common share. Some investors may be eyeing potential gains from the company's dividends. L3Harris currently has a dividend yield of 1.96%. That’s a quarterly dividend amount of $1.16 a share ($4.64 a year). To figure out how to earn $500 monthly
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)
SC 13G/A - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Subject)
10-Q - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
10-Q - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Filer)
Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year 2024 Revenue Guidance(1) to a Range of $61.0 to $64.0 Billion and Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.75 to $2.95 Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(3), Revenues Grew 14% Operationally Third-Quarter 2024 Reported(4) Diluted EPS of $0.78 and Adjusted(2) Diluted EPS of $1.06 On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction Initiatives At Least $4 B
Highlights* Orders of $7.2 billion; book-to-bill of 1.4x Revenue of $5.3 billion, up 8%, and 5% organically Operating margin of 9.4%; adjusted segment operating margin of 15.7% Diluted earnings per share (EPS) of $2.10; non-GAAP diluted EPS of $3.34 2024 revenue guidance range increased to $21.1B - $21.3B 2024 adjusted segment operating margin guidance increased to ~15.5% 2024 non-GAAP diluted EPS guidance range increased to $12.95 - $13.15 L3Harris Technologies (NYSE:LHX) reported third quarter 2024 diluted EPS of $2.10, an increase of 4% from third quarter 2023, on third quarter 2024 revenue of $5.3 billion, an increase of 8%. Third quarter 2024 non-GAAP diluted EPS was $3
The Board of Directors of L3Harris Technologies (NYSE:LHX) has declared a quarterly cash dividend of $1.16 per common share, payable Dec. 6, 2024, to shareholders of record as of the close of business Nov. 18, 2024. About L3Harris Technologies L3Harris Technologies is the Trusted Disruptor in the defense industry. With customers' mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains in the interest of national security. Visit L3Harris.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20241016709252/en/
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
4 - PFIZER INC (0000078003) (Issuer)
4 - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)